Drug Clues for the Treatment of Fungal Catheter-Related Bloodstream Infection With Antifungal Lock Therapy.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S501664

Xiuyun Li, Bing Yu, Hui Li, Zhirui Liu, Xiaohan Fu, Ping Jiao, Lei Wang

{"title":"Drug Clues for the Treatment of Fungal Catheter-Related Bloodstream Infection With Antifungal Lock Therapy.","authors":"Xiuyun Li, Bing Yu, Hui Li, Zhirui Liu, Xiaohan Fu, Ping Jiao, Lei Wang","doi":"10.2147/DDDT.S501664","DOIUrl":null,"url":null,"abstract":"Background: Biofilm formation often represents significant challenges in managing of bloodstream infections associated with catheter use.Objective: Antimicrobial lock therapy serves as an adjunctive treatment for catheter-related infections, effectively eradicating or inhibiting biofilm growth.Methods: This review synthesizes the current knowledge on antifungal lock therapy (ALT) targeting clinically common fungi, primarily Candida species, based on both in vitro and in vivo studies (animals and patients) from the past decade.Results: Amphotericin B (AmB) and echinocandins are identified as the most promising antifungal agents for ALT. Combinations of antifungal agents with other compounds, such as farnesol, Neosartorya fischeri antifungal protein 2, 8-hydroxyquinoline-5-(N-4-chlorophenyl) sulfonamide, and polyurethane, have also shown efficacy in ALT. Additionally, ethanol, doxycycline, tigecycline, and minocycline lock solutions can be effective in treating fungal infections.Conclusion: More comprehensive investigations and additional rigorous clinical trials are essential to thoroughly understand the safety and efficacy of ALT. This will facilitate the development of novel treatments for catheter-related fungal infections, thereby improving clinical outcomes.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"683-701"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792632/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S501664","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biofilm formation often represents significant challenges in managing of bloodstream infections associated with catheter use.

Objective: Antimicrobial lock therapy serves as an adjunctive treatment for catheter-related infections, effectively eradicating or inhibiting biofilm growth.

Methods: This review synthesizes the current knowledge on antifungal lock therapy (ALT) targeting clinically common fungi, primarily Candida species, based on both in vitro and in vivo studies (animals and patients) from the past decade.

Results: Amphotericin B (AmB) and echinocandins are identified as the most promising antifungal agents for ALT. Combinations of antifungal agents with other compounds, such as farnesol, Neosartorya fischeri antifungal protein 2, 8-hydroxyquinoline-5-(N-4-chlorophenyl) sulfonamide, and polyurethane, have also shown efficacy in ALT. Additionally, ethanol, doxycycline, tigecycline, and minocycline lock solutions can be effective in treating fungal infections.

Conclusion: More comprehensive investigations and additional rigorous clinical trials are essential to thoroughly understand the safety and efficacy of ALT. This will facilitate the development of novel treatments for catheter-related fungal infections, thereby improving clinical outcomes.

查看原文本刊更多论文

用抗真菌锁定疗法治疗真菌性导管相关血流感染的药物线索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.